EMS-backed gene therapy developer AvroBio has secured $99.7m in an initial public offering that could potentially rise to $115m.

Rocket Internet remains the largest investor in the home products marketplace, which has floated in a $174m initial public offering.

The UCL spinout has set the pricing range at $15 to $17 and stands to raise nearly $144m in proceeds if underwriters take up their 30-day option.

Kadmon-backed gene therapy developer MeiraGTx has gone public on Nasdaq after raising $75m in proceeds in its initial public offering.

Forty Seven, a GV-backed immuno-oncology spinout from Stanford University, has filed for a $115m initial public offering on Nasdaq just eight months after closing a $75m series B.

United, Mitsui, Itochu and GMO-backed e-commerce platform Mercari has priced its initial public offering at the top of its range and will raise up to $1.19bn in Tokyo this month.

M17 Entertainment, backed by MCN, Yahoo Japan and LeSports, was expected to float on the New York Stock Exchange yesterday but still has not begun trading.

Scholar Rock, a spinal muscular atrophy therapy developer backed by Kraft Group, floated in the middle of its range.

Polyphor, which has collaboration agreements in place with multiple pharmaceutical companies, raised $155m when it floated on the SIX Swiss Exchange.

The Alphabet, Celgene and Mayo Clinic-backed gut-body drug developer floated at the top of its range, after about $167m in VC funding.